Advertisement
Singapore markets closed

  • Straits Times Index

    3,297.55
    -26.98 (-0.81%)
     

  • Nikkei

    38,814.56
    +94.09 (+0.24%)
     

  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     

  • FTSE 100

    8,146.86
    -16.81 (-0.21%)
     

  • Bitcoin USD

    66,096.62
    -82.29 (-0.12%)
     

  • CMC Crypto 200

    1,404.63
    -13.25 (-0.93%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • Dow

    38,589.16
    -57.94 (-0.15%)
     

  • Nasdaq

    17,688.88
    +21.32 (+0.12%)
     

  • Gold

    2,348.40
    +30.40 (+1.31%)
     

  • Crude Oil

    78.49
    -0.13 (-0.17%)
     

  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     

  • FTSE Bursa Malaysia

    1,607.32
    -2.85 (-0.18%)
     

  • Jakarta Composite Index

    6,734.83
    -96.73 (-1.42%)
     

  • PSE Index

    6,383.70
    -7.13 (-0.11%)
     

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Business Wire
·1-min read

REDWOOD CITY, Calif. & BOSTON, May 14, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024.

Details of the poster presentation are as follows:

Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Multiple Solid and Hematological Cancer Indications
Presenting Author: Yvan Chanthery, Ph.D.
Date & Time: June 14, 2024 at 18:00 CEST

ADVERTISEMENT

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514346504/en/

Contacts

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com